FOXP1、STAT3在弥漫大B细胞淋巴瘤中的表达及其预后价值  

Expressions and prognostic values of FOXP1 and STAT3 in diffuse large B-cell lymphoma

作　　者：雷阿明 罗福梅 朱平[1] LEI Aming;LUO Fumei;ZHU Ping(Department of Hematology,The First People's Hospital of Chenzhou,Chenzhou,Hunan 423000,China;Department of Obstetrics,The Fourth People's Hospital of Chenzhou,Chenzhou,Hunan 423000,China)

机构地区：[1]郴州市第一人民医院血液内科,湖南郴州423000 [2]郴州市第四人民医院产科,湖南郴州423000

出　　处：《医药前沿》2025年第13期26-29,共4页Journal of Frontiers of Medicine

基　　金：湘南学院校级科学研究项目(2022JX150)。

摘　　要：目的分析叉头框转录蛋白1(FOXP1)、信号转导和转录活化因子3(STAT3)在弥漫大B细胞淋巴瘤(DLBCL)中的表达及其对患者生存时间的影响。方法选取2021年10月—2022年12月郴州市第一人民医院收治的60例DLBCL患者作为研究组,选取同期收治的反应性增生淋巴结患者60例作为对照组,并选取同期60名健康检查的志愿者作为健康组。使用免疫组织化学法测定三组研究对象组织中的FOXP1、STAT3表达情况。研究组患者均随访至2023年7月,通过来院复诊和电话随访患者预后状况及总生存时间(OS),比较不同疗效患者的FOXP1、STAT3阳性表达情况,并利用Kaplan-Meier生存曲线分析FOXP1、STAT3表达对DLBCL患者生存时间的影响。结果研究组患者的FOXP1、STAT3表达水平高于对照组和健康组,且对照组患者的FOXP1、STAT3表达水平高于健康组,差异有统计学意义(P<0.05);研究组疾病进展(PD)患者的FOXP1、STAT3阳性表达率高于疾病稳定(SD)、部分缓解(PR)、完全缓解(CR)患者,且SD患者的FOXP1、STAT3阳性表达率高于PR、CR患者,PR患者的FOXP1、STAT3阳性表达率高于CR患者,差异有统计学意义(P<0.05)。研究组患者随访18个月,无进展生存(PFS)率为61.67%(37/60),OS率为76.67%(46/60)。DLBLC患者中FOXP1及STAT3表达阳性患者的OS率降低。结论DLBCL组织中FOXP1表达阳性及STAT3表达阳性提示患者生存率降低。Objective To analyze the expressions of forkhead box protein P1(FOXP1)and signal transducer and activator of transcription 3(STAT3)in diffuse large B-cell lymphoma(DLBCL)and their effects on patients’survival time.Methods A total of 60 DLBCL patients admitted to The First People's Hospital of Chenzhou from October 2021 to December 2022 were enrolled as the study group,while 60 patients with reactive hyperplasia of lymph node admitted during the same period were selected as the control group,and 60 volunteers who underwent health examinations during the same period were selected as the healthy group.Expressions of FOXP1 and STAT3 in tissue samples were detected by using immunohistochemistry method.The patients in the study group were followed up until July 2023.The prognoses and overall survival(OS)of the patients were followed up by return visit and telephone follow-up.The positive expressions of FOXP1 and STAT3 were compared among patients with different treatment responses.Kaplan-Meier survival curve was used to evaluate the effects of FOXP1 and STAT3 expressions on survival times of DLBCL patients.Results Expression levels of FOXP1 and STAT3 in the study group were higher than those in the control and healthy groups,and the levels in the control group were higher than those in the healthy group,and the differences were statistically significant(P<0.05).In the study group,the positive expression rates of FOXP1 and STAT3 in DLBCL patients with progressive disease(PD)were higher than those in patients with stable disease(SD),partial response(PR),and complete response(CR),and the positive expression rates of FOXP1 and STAT3 in SD patients were higher than those in PR and CR patients,while the positive expression rates of FOXP1 and STAT3 in PR patients were higher than those in CR patients,and the differences were statistically significant(P<0.05).After 18-month of follow-up,progression-free survival(PFS)and OS rates of the patients in the study group were 61.67%(37/60)and 76.67%(46/60),respectively.OS rates in D

关 键 词：弥漫大B细胞淋巴瘤 叉头框转录蛋白1 信号转导和转录活化因子3 免疫组织化学 生存分析 

分 类 号：R733[医药卫生—肿瘤]